Masamichi Takami

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4552975/publications.pdf

Version: 2024-02-01

94 papers	5,206 citations	159358 30 h-index	88477 70 g-index
99 all docs	99 docs citations	99 times ranked	5502 citing authors

#	Article	IF	Citations
1	Neural crest-derived cells possess differentiation potential to keratinocytes in the process of wound healing. Biomedicine and Pharmacotherapy, 2022, 146, 112593.	2.5	5
2	Effects of Antiâ€“Receptor Activator of Nuclear Factor Kappa B Ligand Antibody and Zoledronic Acid on Periapical Lesion Development in Mice. Journal of Endodontics, 2022, 48, 632-640.	1.4	6
3	Inhibition of hepatocyte growth factor/c-Met signalling abrogates joint destruction by suppressing monocyte migration in rheumatoid arthritis. Rheumatology, 2021, 60, 408-419.	0.9	6
4	Pax5 Negatively Regulates Osteoclastogenesis through Downregulation of Blimp1. International Journal of Molecular Sciences, 2021, 22, 2097.	1.8	7
5	Neural crest-derived cells in nasal conchae of adult mice contribute to bone regeneration. Biochemical and Biophysical Research Communications, 2021, 554, 173-178.	1.0	4
6	Novel gene Merlot inhibits differentiation and promotes apoptosis of osteoclasts. Bone, 2020, 138, 115494.	1.4	8
7	Effects of lipid metabolism on mouse incisor dentinogenesis. Scientific Reports, 2020, 10, 5102.	1.6	5
8	Lipopolysaccharide (LPS) inhibits ectopic bone formation induced by bone morphogenetic protein-2 and TGF-Î²1 through IL-1Î² production. Journal of Oral Biosciences, 2020, 62, 44-51.	0.8	5
9	Myelination during fracture healing in vivo in myelin protein zero (p0) transgenic medaka line. Bone, 2020, 133, 115225.	1.4	10
10	Effects of N-methyl-d-aspartate receptor antagonist MK-801 (dizocilpine) on bone homeostasis in mice. Journal of Oral Biosciences, 2020, 62, 131-138.	0.8	3
11	Treatment with synthetic glucocorticoid impairs bone metabolism, as revealed by in vivo imaging of osteoblasts and osteoclasts in medaka fish. Biomedicine and Pharmacotherapy, 2019, 118, 109101.	2.5	13
12	Roles of monocarboxylate transporter subtypes in promotion and suppression of osteoclast differentiation and survival on bone. Scientific Reports, 2019, 9, 15608.	1.6	8
13	A Delphinidin-Enriched Maqui Berry Extract Improves Bone Metabolism and Protects against Bone Loss in Osteopenic Mouse Models. Antioxidants, 2019, 8, 386.	2.2	19
14	Bone loss caused by dopaminergic degeneration and levodopa treatment in Parkinsonâ€™s disease model mice. Scientific Reports, 2019, 9, 13768.	1.6	30
15	Singleton-Merten Syndromeâ€“like Skeletal Abnormalities in Mice with Constitutively Activated MDA5. Journal of Immunology, 2019, 203, 1356-1368.	0.4	17
16	Biological Effects of Anti-RANKL Antibody and Zoledronic Acid on Growth and Tooth Eruption in Growing Mice. Scientific Reports, 2019, 9, 19895.	1.6	11
17	In Vitro Study of the Effects of Denosumab on Giant Cell Tumor of Bone: Comparison with Zoledronic Acid. Pathology and Oncology Research, 2019, 25, 409-419.	0.9	29
18	Disruption of the mouse Slc39a14 gene encoding zinc transporter <scp>ZIP</scp>14 is associated with decreased bone mass, likely caused by enhanced bone resorption. FEBS Open Bio, 2018, 8, 655-663.	1.0	10

#	Article	IF	Citations
19	Anti-mouse RANKL Antibodies Inhibit Alveolar Bone Destruction in Periodontitis Model Mice. Biological and Pharmaceutical Bulletin, 2018, 41, 637-643.	0.6	21
20	The inhibition of malignant melanoma cell invasion of bone by the TLR7 agonist R848 is dependent upon pro-inflammatory cytokines produced by bone marrow macrophages. Oncotarget, 2018, 9, 29934-29943.	0.8	8
21	Effects of Anti-RANKL Antibody and Zoledronate on Development of Young Mice. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-4-39.	0.0	0
22	Administration of anti-RANKL antibody to pregnant mice results in impaired development of mammary gland and death of newborns. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, PO1-4-38.	0.0	0
23	LPS administration increases CD11b+ c-Fms+ CD14+ cell population that possesses osteoclast differentiation potential in mice. Cytotechnology, 2017, 69, 529-537.	0.7	3
24	Biological effects of anti-RANKL antibody administration in pregnant mice and their newborns. Biochemical and Biophysical Research Communications, 2017, 491, 614-621.	1.0	23
25	Down-regulation of Irf8 by Lyz2-cre/loxP accelerates osteoclast differentiation in vitro. Cytotechnology, 2017, 69, 443-450.	0.7	13
26	Induction of osteoblastic differentiation of neural crest-derived stem cells from hair follicles. PLoS ONE, 2017, 12, e0174940.	1.1	15
27	Interaction of Tumor Necrosis Factor Receptor-associated Factor 6 (TRAF6) and Vav3 in the Receptor Activator of Nuclear Factor Î¹B (RANK) Signaling Complex Enhances Osteoclastogenesis. Journal of Biological Chemistry, 2016, 291, 20643-20660.	1.6	19
28	Smad4 is required to inhibit osteoclastogenesis and maintain bone mass. Scientific Reports, 2016, 6, 35221.	1.6	17
29	Expression of nephronectin is enhanced by 1Î±,25â€dihydroxyvitamin D 3. FEBS Open Bio, 2016, 6, 914-918.	1.0	5
30	Conditional deletion of CD98hc inhibits osteoclast development. Biochemistry and Biophysics Reports, 2016, 5, 203-210.	0.7	2
31	Bropirimine inhibits osteoclast differentiation through production of interferon-Î². Biochemical and Biophysical Research Communications, 2015, 467, 146-151.	1.0	2
32	Microscopic study on resorption of Î²-tricalcium phosphate materials by osteoclasts. Cytotechnology, 2015, 67, 727-732.	0.7	14
33	Localization and osteoblastic differentiation potential of neural crest-derived cells in oral tissues of adult mice. Biochemical and Biophysical Research Communications, 2015, 464, 1209-1214.	1.0	14
34	Expression of nephronectin is inhibited by oncostatin M via both JAK/STAT and MAPK pathways. FEBS Open Bio, 2015, 5, 303-307.	1.0	15
35	Secretion of a Truncated Osteopetrosis-associated Transmembrane Protein 1 (OSTM1) Mutant Inhibits Osteoclastogenesis through Down-regulation of the B Lymphocyte-induced Maturation Protein 1 (BLIMP1)-Nuclear Factor of Activated T Cells c1 (NFATc1) Axis. Journal of Biological Chemistry, 2014, 289, 35868-35881.	1.6	24
36	Porphyromonas gingivalis-derived Lysine Gingipain Enhances Osteoclast Differentiation Induced by Tumor Necrosis Factor-Î± and Interleukin-1Î² but Suppresses That by Interleukin-17A. Journal of Biological Chemistry, 2014, 289, 15621-15630.	1.6	40

#	Article	IF	Citations
37	Octacalcium phosphate suppresses chondrogenic differentiation of ATDC5 cells. Cell and Tissue Research, 2013, 352, 401-412.	1.5	14
38	Downregulation of Carbonic Anhydrase IX Promotes Col10a1 Expression in Chondrocytes. PLoS ONE, 2013, 8, e56984.	1.1	5
39	Suppressive Effects of the Leaf of Terminalia catappa L. on Osteoclast Differentiation In Vitro and Bone Weight Loss In Vivo. Journal of Nutritional Science and Vitaminology, 2012, 58, 129-135.	0.2	3
40	Nephronectin expression is regulated by SMAD signaling in osteoblast-like MC3T3-E1 cells. Biochemical and Biophysical Research Communications, 2012, 425, 390-392.	1.0	11
41	D-chiro-inositol Negatively Regulates the Formation of Multinucleated Osteoclasts by Down-Regulating NFATc1. Journal of Clinical Immunology, 2012, 32, 1360-1371.	2.0	15
42	Cell Adhesion Signaling Regulates RANK Expression in Osteoclast Precursors. PLoS ONE, 2012, 7, e48795.	1.1	26
43	R848, a toll-like receptor 7 agonist, inhibits osteoclast differentiation but not survival or bone-resorbing function of mature osteoclasts. Cytotechnology, 2012, 64, 331-339.	0.7	11
44	BMP2 Differentially Regulates the Expression of Gremlin1 and Gremlin2, the Negative Regulators of BMP Function, During Osteoblast Differentiation. Calcified Tissue International, 2012, 91, 88-96.	1.5	25
45	Expression of POEM, a positive regulator of osteoblast differentiation, is suppressed by TNF-Î±. Biochemical and Biophysical Research Communications, 2011, 410, 766-770.	1.0	22
46	Splenic extramedullary hemopoiesis caused by a dysfunctional mutation in the NF-ÎºB-inducing kinase gene. Biochemical and Biophysical Research Communications, 2011, 414, 773-778.	1.0	7
47	Shared and Distinct Functions of the Transcription Factors IRF4 and IRF8 in Myeloid Cell Development. PLoS ONE, 2011, 6, e25812.	1.1	78
48	Feedback inhibition of osteoclastogenesis during inflammation by ILâ€10, Mâ€CSF receptor shedding, and induction of IRF8. Annals of the New York Academy of Sciences, 2011, 1237, 88-94.	1.8	27
49	Enhancement of Bone Morphogenetic Protein-2-Induced Ectopic Bone Formation by Transforming Growth Factor-Î²1. Tissue Engineering - Part A, 2011, 17, 597-606.	1.6	85
50	Monocarboxylate Transporter-1 Is Required for Cell Death in Mouse Chondrocytic ATDC5 Cells Exposed to Interleukin-1Î² via Late Phase Activation of Nuclear Factor ÎºB and Expression of Phagocyte-type NADPH Oxidase. Journal of Biological Chemistry, 2011, 286, 14744-14752.	1.6	24
51	Honokiol Inhibits Osteoclast Differentiation and Function in Vitro. Biological and Pharmaceutical Bulletin, 2010, 33, 487-492.	0.6	25
52	Bone morphogenetic protein 2 enhances mouse osteoclast differentiation via increased levels of receptor activator of NF-ÎºB ligand expression in osteoblasts. Cell and Tissue Research, 2010, 342, 213-220.	1.5	30
53	Osteoclast Differentiation Induced by Synthetic Octacalcium Phosphate Through Receptor Activator of NF-ÎºB Ligand Expression in Osteoblasts. Tissue Engineering - Part A, 2009, 15, 3991-4000.	1.6	83
54	Interferon regulatory factor-8 regulates bone metabolism by suppressing osteoclastogenesis. Nature Medicine, 2009, 15, 1066-1071.	15.2	270

#	Article	IF	Citations
55	IFN-Î³ down-regulates Secretoglobin 3A1 gene expression. Biochemical and Biophysical Research Communications, 2009, 379, 964-968.	1.0	6
56	Lysine-specific gingipain promotes lipopolysaccharide- and active-vitamin D3-induced osteoclast differentiation by degrading osteoprotegerin. Biochemical Journal, 2009, 419, 159-166.	1.7	40
57	Characterization of synovial cell clones isolated from rheumatoid arthritis patients: Possible involvement of TNF-Î± in reduction of osteoprotegerin in synovium. Cytokine, 2008, 41, 61-70.	1.4	7
58	The identification of an osteoclastogenesis inhibitor through the inhibition of glyoxalase I. Proceedings of the National Academy of Sciences of the United States of America, 2008, 105, 11691-11696.	3.3	125
59	Effects of Mechanical Strain on Differentiation of Osteoblastic Cells. , 2008, , .		0
60	Osteoclast Generation. , 2008, , 175-192.		2
61	Nitric Oxide in Pulp Cell Growth, Differentiation, and Mineralization. Journal of Dental Research, 2007, 86, 163-168.	2.5	29
62	Heparin enhances osteoclastic bone resorption by inhibiting osteoprotegerin activity. Bone, 2007, 41, 165-174.	1.4	101
63	TGFâ€Î²2 suppresses POEM expression through ERK1/2 and JNK in osteoblasts. FEBS Letters, 2007, 581, 5321-5326.	1.3	21
64	Interleukin-4 inhibition of osteoclast differentiation is stronger than that of interleukin-13 and they are equivalent for induction of osteoprotegerin production from osteoblasts. Immunology, 2007, 120, 573-579.	2.0	89
65	Identification of two biologically crucial hydroxyl groups of (â^')-epigallocatechin gallate in osteoclast culture. Biochemical Pharmacology, 2007, 73, 34-43.	2.0	29
66	Analogs of 1Î±,25-dihydroxyvitamin D3 with high potency in induction of osteoclastogenesis and prevention of dendritic cell differentiation: Synthesis and biological evaluation of 2-substituted 19-norvitamin D analogs. Bioorganic and Medicinal Chemistry, 2006, 14, 4645-4656.	1.4	12
67	Reveromycin A, an agent for osteoporosis, inhibits bone resorption by inducing apoptosis specifically in osteoclasts. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 4729-4734.	3.3	79
68	Identification and Characterization of the Precursors Committed to Osteoclasts Induced by TNF-Related Activation-Induced Cytokine/Receptor Activator of NF-ÎºB Ligand. Journal of Immunology, 2006, 177, 4360-4368.	0.4	38
69	Interleukin-1Î² induces death in chondrocyte-like ATDC5 cells through mitochondrial dysfunction and energy depletion in a reactive nitrogen and oxygen species-dependent manner. Biochemical Journal, 2005, 389, 315-323.	1.7	101
70	Osteoclast differentiation independent of the TRANCEâ€"RANKâ€"TRAF6 axis. Journal of Experimental Medicine, 2005, 202, 589-595.	4.2	335
71	Differentiation and function of osteoclasts cultured on bone and cartilage. Journal of Electron Microscopy, 2005, 54, 529-540.	0.9	12
72	Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways. FEBS Letters, 2005, 579, 832-838.	1.3	59

#	Article	IF	Citations
73	Suppression of Osteoprotegerin Expression by Prostaglandin E2 Is Crucially Involved in Lipopolysaccharide-Induced Osteoclast Formation. Journal of Immunology, 2004, 172, 2504-2510.	0.4	145
74	Disabling of Receptor Activator of Nuclear Factor-Î¹B (RANK) Receptor Complex by Novel Osteoprotegerin-like Peptidomimetics Restores Bone Loss in Vivo. Journal of Biological Chemistry, 2004, 279, 8269-8277.	1.6	83
75	Dimer formation of receptor activator of nuclear factor Î¹B induces incomplete osteoclast formation. Biochemical and Biophysical Research Communications, 2004, 325, 229-234.	1.0	18
76	Osteoimmunology: interactions of the immune and skeletal systems. Molecules and Cells, 2004, 17, 1-9.	1.0	108
77	Involvement of vacuolar H+-ATPase in incorporation of risedronate into osteoclasts. Bone, 2003, 32, 341-349.	1.4	29
78	Destruxins, cyclodepsipeptides, block the formation of actin rings and prominent clear zones and ruffled borders in osteoclasts. Bone, 2003, 33, 443-455.	1.4	35
79	Lipopolysaccharide Promotes the Survival of Osteoclasts Via Toll-Like Receptor 4, but Cytokine Production of Osteoclasts in Response to Lipopolysaccharide Is Different from That of Macrophages. Journal of Immunology, 2003, 170, 3688-3695.	0.4	168
80	p38 Mitogen-Activated Protein Kinase Is Crucially Involved in Osteoclast Differentiation But Not in Cytokine Production, Phagocytosis, or Dendritic Cell Differentiation of Bone Marrow Macrophages. Endocrinology, 2003, 144, 4999-5005.	1.4	79
81	Stimulation by Toll-Like Receptors Inhibits Osteoclast Differentiation. Journal of Immunology, 2002, 169, 1516-1523.	0.4	216
82	A Novel Member of the Leukocyte Receptor Complex Regulates Osteoclast Differentiation. Journal of Experimental Medicine, 2002, 195, 201-209.	4.2	250
83	Gene Expression Profiling of Osteoclast Differentiation by Combined Suppression Subtractive Hybridization (SSH) and cDNA Microarray Analysis. DNA and Cell Biology, 2002, 21, 541-549.	0.9	63
84	Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. The Anatomical Record, 2002, 268, 137-146.	2.3	55
85	Lipopolysaccharide supports survival and fusion of preosteoclasts independent of TNF-?, IL-1, and RANKL. Journal of Cellular Physiology, 2002, 190, 101-108.	2.0	110
86	Cells of Bone. , 2002, , 109-126.		38
87	Importance of Membraneâ€•or Matrixâ€Associated Forms of Mâ€CSF and RANKL/ODF in Osteoclastogenesis Supported by SaOSâ€4/3 Cells Expressing Recombinant PTH/PTHrP Receptors. Journal of Bone and Mineral Research, 2000, 15, 1766-1775.	3.1	84
88	Receptor activator of NF-kappaB ligand induces the fusion of mononuclear preosteoclasts into multinucleated osteoclasts. Cytotechnology, 2000, 33, 203-211.	0.7	2
89	Tumor Necrosis Factor Î± Stimulates Osteoclast Differentiation by a Mechanism Independent of the Odf/Ranklâ€“Rank Interaction. Journal of Experimental Medicine, 2000, 191, 275-286.	4.2	1,219
90	Intracellular Calcium and Protein Kinase C Mediate Expression of Receptor Activator of Nuclear Factor-Î¹B Ligand and Osteoprotegerin in Osteoblasts. Endocrinology, 2000, 141, 4711-4719.	1.4	85

#	Article	IF	Citations
91	Cytotoxic effects of NSL-1406, a new thienopyrimidine derivative, on leukocytes and osteoclasts. Bioorganic and Medicinal Chemistry Letters, 1999, 9, 797-802.	1.0	33
92	Osteoblastic cells induce fusion and activation of osteoclasts through a mechanism independent of macrophage-colony-stimulating factor production. Cell and Tissue Research, 1999, 298, 327-334.	1.5	44
93	Requirement of osteoblastic cells for the fusion of preosteoclasts. Journal of Bone and Mineral Metabolism, 1998, 16, 151-157.	1.3	11
94	Ca2+-ATPase Inhibitors and Ca2+-Ionophore Induce Osteoclast-like Cell Formation in the Cocultures of Mouse Bone Marrow Cells and Calvarial Cells. Biochemical and Biophysical Research Communications, 1997, 237, 111-115.	1.0	23